These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29868865)

  • 21. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
    Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
    Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS; To KW; Lee MP; Wong NS; Chan DP; Li PC; Cheung SW; Chan RC
    Int J STD AIDS; 2014 Mar; 25(3):193-200. PubMed ID: 23970651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
    Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.
    Bienczak A; Cook A; Wiesner L; Olagunju A; Mulenga V; Kityo C; Kekitiinwa A; Owen A; Walker AS; Gibb DM; McIlleron H; Burger D; Denti P
    Br J Clin Pharmacol; 2016 Jul; 82(1):185-98. PubMed ID: 26991336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
    J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
    Ximenez JP; Elias ABR; Nardotto GHB; Barroso PF; Bollela VR; Lanchote VL; Suarez-Kurtz G
    Br J Clin Pharmacol; 2022 Oct; 88(10):4585-4594. PubMed ID: 35514050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity.
    Petros Z; Habtewold A; Makonnen E; Aklillu E
    Sci Rep; 2022 Jun; 12(1):9698. PubMed ID: 35690682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
    Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
    Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
    Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
    Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz in the therapy of HIV infection.
    Rakhmanina NY; van den Anker JN
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):95-103. PubMed ID: 20001610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
    van Rensburg R; Nightingale S; Brey N; Albertyn CH; Kellermann TA; Taljaard JJ; Esterhuizen TM; Sinxadi PZ; Decloedt EH
    Clin Infect Dis; 2022 Aug; 75(3):399-405. PubMed ID: 34882770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.
    Naidoo P; Chetty VV; Chetty M
    Eur J Clin Pharmacol; 2014 Apr; 70(4):379-89. PubMed ID: 24390631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
    Adegbola AJ; Rana A; Adeagbo BA; Bolarinwa RA; Olagunju AE; Siccardi M; Owen A; Bolaji OO
    Pharmacogenet Genomics; 2020 Jul; 30(5):96-106. PubMed ID: 32209837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.